
Graph AI, the developer of the AI-powered Graph Safety patient safety platform, has raised $13.3 million in Series A funding.
The round was led by Insight Partners with participation from existing investor Bessemer Venture Partners.
Founded in 2024, Graph AI helps pharmaceutical and biotechnology companies automate complex pharmacovigilance and patient safety workflows. These teams often spend significant time on manual case processing and regulatory tasks.
Graph Safety combines AI with built-in controls, validation systems and audit trails to help safety teams automate work while maintaining human oversight and traceability. The platform is designed for regulated environments where data and AI-generated results need to be clearly documented and reviewed.
The company says its technology has reduced adverse-event case processing time from more than three hours to under 10 minutes, representing a reduction of over 90%. It has also helped customers reduce operating costs by up to 66%.
Since its seed round in October 2025, Graph AI has launched two modules: /intake which captures and sorts adverse-event reports and /nucleus which automates safety case processing. The company is also launching /report for automated aggregate reporting.
“Pharma companies must strive to get patient safety exactly right, and almost none of them want to be in the business of integrating disparate tools to do it. Meanwhile the software and service providers they rely on haven’t kept up with what AI can now do to drive accuracy and value for their pharma customers,” said Richard Matus, Principal at Insight Partners. “We believe that’s a perfect problem for an AI team that lives inside this industry with complete focus, and why we’re proud to back Raghav and the Graph AI team as they scale.”
“Since leading Graph AI’s seed round, we’ve watched Raghav and the team turn a bold thesis into live enterprise deployments with measurable outcomes. Patient safety should run an intelligent, integrated platform – not fragmented tools and manual handoffs. We are thrilled to deepen our partnership alongside Insight Partners as Graph scales globally. This is what AI disrupting a services-heavy industry looks like.” said Nithin Kaimal, Partner and India COO at Bessemer Venture Partners.
“Pharmacovigilance has traditionally scaled against rising case volumes by adding people and processes around legacy systems. We believe intelligence can change that. Graph Safety gives safety experts an intelligent system that takes on operational complexity, while keeping traceability, accountability, and human oversight at the center. We are not replacing human judgment—we are building technology that allows experts to apply it where it matters most,” said Raghav Parvataraju, CEO, Graph AI.
Graph AI has customers across the pharmaceutical and biotech industries in North America and other markets. The company has also formed design partnerships for future products, including /signal, which is designed to identify emerging safety signals and patterns across patient cases.
The new funding will support Graph AI as it expands its AI-powered patient safety platform and develops additional products for pharmaceutical and biotechnology companies.